Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias (POE07-01)
Sponsor: Genzyme, a Sanofi Company
Terminated
Lack of accrual
Other terminated trials from Genzyme, a Sanofi Company
Other Acute Leukemia trials with similar outcome
A PHASE1 clinical study on Acute Leukemia and Acute Lymphocytic Leukemia, this trial is terminated or withdrawn. The trial is conducted by Genzyme, a Sanofi Company and has accumulated 7 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Terminated PHASE1
Status: Unknown Status → Terminated
▶ Show 2 earlier versions
-
Feb 2017 — Mar 2018 [monthly]
Unknown Status PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE1
First recorded
Sep 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genzyme, a Sanofi Company
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
For direct contact, visit the study record on ClinicalTrials.gov .